Valuation: Myriad Genetics, Inc.

Market Cap 551M 492M 455M 412M 771M 52.3B 783M 5.47B 2.17B 27.4B 2.07B 2.02B 86.39B P/E 2026 *
-3.68x
P/E 2027 * -4.41x
Enterprise Value 502M 448M 414M 375M 702M 47.65B 714M 4.98B 1.97B 24.97B 1.88B 1.84B 78.71B EV / Sales 2026 *
0.65x
EV / Sales 2027 * 0.59x
Free-Float
95.99%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
1 week+45.98%
Current month+34.80%
1 month+44.89%
3 months+1.93%
6 months+21.29%
Current year-5.53%
1 week 3.95
Extreme 3.95
5.95
1 month 3.95
Extreme 3.95
5.95
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.5
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
32.68
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Tax

Chief Financial Officer

-2,555 0.0027%
9/16/26 Free

Executive/Senior Manager

257,731 0.2695%
9/16/26 Other

Executive/Senior Manager

93,493 0.0977%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+45.98%-27.83%-62.00% 533M
+0.56%-2.16%-18.77%+7.15% 177B
-0.50%+1.27%+1.85%+32.55% 118B
+0.64%+4.65%-19.50%+17.00% 118B
+2.29%+17.36%-41.94%+9.49% 91.21B
-1.13%-1.83%+1.86%+77.25% 64.59B
-1.06%+4.59%+13.36%+78.58% 56.13B
-0.61%+3.70%+6.60%-22.31% 54.59B
-0.76%-0.02%-12.27%+30.98% 43.6B
+0.17%+5.85%-4.92%-10.64% 33.95B
Average +0.10%+7.04%-10.16%+15.80% 75.8B
Weighted average by Cap. +0.17%+3.57%-11.50%+22.59%

Financials

2026 *2027 *
Net sales 778M 695M 642M 582M 1.09B 73.85B 1.11B 7.72B 3.06B 38.69B 2.92B 2.86B 122B 820M 733M 677M 613M 1.15B 77.89B 1.17B 8.14B 3.22B 40.81B 3.08B 3.01B 129B
Net income -140M -125M -115M -104M -195M -13.25B -198M -1.39B -549M -6.94B -524M -513M -21.89B -106M -94.86M -87.63M -79.41M -149M -10.08B -151M -1.05B -417M -5.28B -399M -390M -16.66B
Net Debt -48.99M -43.74M -40.41M -36.62M -68.52M -4.65B -69.65M -486M -193M -2.44B -184M -180M -7.68B -67.76M -60.51M -55.9M -50.66M -94.77M -6.43B -96.34M -673M -266M -3.37B -254M -249M -10.62B
Projected Income Statement - Annual - Myriad Genetics, Inc.
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-10-23 US$5.800 +0.69% 500,205
26-10-22 US$5.760 +3.41% 4,439,953
26-10-21 US$5.570 +0.54% 4,951,629
26-10-20 US$5.540 +31.59% 24,004,019
26-10-19 US$4.210 +5.78% 1,355,836
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Myriad Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
5.760USD
Average target price
4.488USD
Spread / Average Target
-22.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Myriad Genetics, Inc.
  1. Stock Market
  2. Stocks
  3. MYGN Stock